ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL953
CHEMBL953
Compound Name ENTACAPONE
ChEMBL Synonyms COMTAN | ENTACAPONE | OR-611
Max Phase 4 (Approved)
Trade Names ENTACAPONE | COMTAN
Molecular Formula C14H15N3O5

Additional synonyms for CHEMBL953 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CCN(CC)C(=O)\C(=C\c1cc(O)c(O)c(c1)[N+](=O)[O-])\C#N
Standard InChI InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21 ...
Download InChI
Standard InChI Key JRURYQJSLYLRLN-BJMVGYQFSA-N

Sources

  • British National Formulary
  • Curated Drug Pharmacokinetic Data
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL953

Molecule Features

CHEMBL953 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Achiral Molecule Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Catechol O-methyltransferase inhibitor Catechol O-methyltransferase DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
OBESITYD009765EFO:0001073OBESITY1ClinicalTrials
EPILEPSYD004827EFO:0000474EPILEPSY1ClinicalTrials
AMPHETAMINE-RELATED DISORDERSD019969EFO:0004701METAMPHETAMINE DEPENDENCE0ClinicalTrials
PARKINSON DISEASED010300EFO:0002508PARKINSON'S DISEASE4ATC
ClinicalTrials

Clinical Data

ClinicalTrials.gov ENTACAPONE
The Cochrane Collaboration ENTACAPONE

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
305.3 305.1012 1.66 5 130.38 ACID


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
6 2 0 8 2 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
5.15 - 2.12 .1 1 22 0.28

Structural Alerts

There are 13 structural alerts for CHEMBL953. To view alerts please click here.

Compound Cross References

ATC N - NERVOUS SYSTEM
N04 - ANTI-PARKINSON DRUGS
N04B - DOPAMINERGIC AGENTS
N04BX - Other dopaminergic agents
N04BX02 - entacapone

ChemSpider ChemSpider:JRURYQJSLYLRLN-BJMVGYQFSA-N
DailyMed entacapone
PubChem SID: 144205737 SID: 170464850 SID: 26757974
Wikipedia Entacapone

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL953



ACToR 116314-67-1 130929-57-6
BindingDB 50108879
Brenda 17740
ChEBI 4798
DrugBank DB00494
DrugCentral 1018
eMolecules 27345033
EPA CompTox Dashboard DTXSID5046439
FDA SRS 4975G9NM6T
Guide to Pharmacology 6647
Human Metabolome Database HMDB0012226
KEGG Ligand C07943
LINCS LSM-43240
PharmGKB PA164748726
PubChem 5281081
PubChem: Drugs of the Future 12014660
PubChem: Thomson Pharma 14776335
Selleck entacapone
SureChEMBL SCHEMBL34504
ZINC ZINC000035342787

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/JRURYQJSLYLRLN-BJMVGYQFSA-N spacer
spacer